Broadly neutralizing antibodies against HIV: New insights to inform vaccine design

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 185-200

  Sadanand, Saheli ^a   Suscovich, Todd J ^a   Alter, Galit ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

B cells; Broadly neutralizing antibodies; Env; HIV vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY DETECTION; ANTIBODY STRUCTURE; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG DESIGN; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; B LYMPHOCYTE; DRUG DEVELOPMENT; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE EVASION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; DRUG DISCOVERY; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; IMMUNITY, HUMORAL; IMMUNIZATION; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS;

EID: 84954553168     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-091014-090749     Document Type: Article

References (88)

1. Siegrist CA. (2008). Vaccine immunology. Vaccines, ed. SA Plotkin, WA Orenstein, PA Offit, pp. 17-36. Philadelphia: Elsevier Saunders. 5th e.d
2. Frost SDW, Wrin T, Smith DM, et al. (2005). Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. PNAS 102(51): 18514-19
3. Mascola JR, Haynes BF. (2013). HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol. Rev. 254(1): 225-44
4. Nimmerjahn F, Ravetch J. (2007). Fc? receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47
5. Checkley MA, Luttge BG, Freed EO. (2011). HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J. Mol. Biol. 410(4): 582-608
6. Perelson AS, Essunger P, Ho DD. (1997). Dynamics of HIV-1 and CD4+ lymphocytes in vivo. AIDS 11(Suppl. A): S17-S24
7. Perelson AS, Neumann AU, Markowitz M, et al. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255): 1582-86
8. Sattentau QJ. (2014). Immunogen design to focus the B-cell repertoire. Curr. Opin. HIV AIDS 9(3): 217-23
9. Eroshkin AM, LeBlanc A, Weekes D, et al. (2014). BNAber: database of broadly neutralizing HIV antibodies. Nucleic Acids Res. 42(Database issue): D1133-39
10. Scharf L, Scheid JF, Lee JH, et al. (2014). Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 7(3): 785-95
11. Huang J, Kang BH, Pancera M, et al. (2014). Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 515(7525): 138-42
12. Klein F, Diskin R, Scheid JF, et al. (2013). Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153(1): 126-38
13. Mouquet H, Scheid JF, Zoller MJ, et al. (2010). Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467(7315): 591-95
14. Wu X, Zhang Z, Schramm CA, et al. (2015). Maturation and diversity of the VRC01-Antibody lineage over 15 years of chronic HIV-1 infection. Cell 161(3): 470-85
15. Lingwood D, McTamney PM, Yassine HM, et al. (2012). Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489(7417): 566-70
16. Scheepers C, Shrestha RK, Lambson BE, et al. (2015). Ability to develop broadly neutralizing HIV-1 antibodies is not restricted by the germline Ig gene repertoire. J. Immunol. 194: 4371-78
17. Pavri R, Nussenzweig MC. (2011). AID targeting in antibody diversity. Adv. Immunol. 110: 1-26
18. Sok D, Laserson U, Laserson J, et al. (2013). The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog. 9(11): e1003754
19. vanMontfort T, Eggink D, Boot M, et al. (2011). HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation. J. Immunol. 187(9): 4676-85
20. Breden F, Lepik C, Longo NS, et al. (2011). Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS ONE 6(3): e16857
21. Horiya S, MacPherson IS, Krauss IJ. (2014). Recent strategies targeting HIV glycans in vaccine design. Nat. Chem. Biol. 10(12): 990-99
22. Georgiev IS, Rudicell RS, Saunders KO, et al. (2014). Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. J. Immunol. 192(3): 1100-6
23. Wu TT, Johnson G, Kabat EA. (1993). Length distribution of CDRH3 in antibodies. Proteins 16(1): 1-7
24. Icenogle J, Shiwen H, Duke G, et al. (1983). Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology 127(2): 412-25
25. Wang F, Ekiert DC, Ahmad I, et al. (2013). Reshaping antibody diversity. Cell 153(6): 1379-93
26. Schofield DJ, Stephenson JR, Dimmock NJ. (1997). Variations in the neutralizing and haemagglutinationinhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J. Gen. Virol. 78(Pt 10): 2431-39
27. Galimidi RP, Klein JS, Politzer MS, et al. (2015). Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell 160(3): 433-46
28. Lynch RM, Tran L, Louder MK, et al. (2012). The development of CD4 binding site antibodies during HIV-1 infection. J. Virol. 86(14): 7588-95
29. Briney BS, Willis JR, Crowe JE. (2012). Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS ONE 7(5): e36750
30. Doria-Rose NA, Klein RM, Manion MM, et al. (2009). Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J. Virol. 83(1): 188-99
31. Sather DN, Armann J, Ching LK, et al. (2009). Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83(2): 757-69
32. Montezuma-Rusca JM, Moir S, Kardava L, et al. (2015). Bone marrow plasma cells are a primary source of serum HIV-1-specific antibodies in chronically infected individuals. J. Immunol. 194(6): 2561-68
33. Pejchal R, Walker LM, Stanfield RL, et al. (2010). Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. PNAS 107(25): 11483-88
34. Fairfax KA, Kallies A, Nutt SL, et al. (2008). Plasma cell development: from B-cell subsets to long-Term survival niches. Semin. Immunol. 20(1): 49-58
35. Scheid JF, Mouquet H, Feldhahn N, et al. (2009). Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458(7238): 636-40
36. Haynes BF, Fleming J, St Clair EW, et al. (2005). Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308(5730): 1906-8
37. Scheid JF, Mouquet H, Ueberheide B, et al. (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333(6049): 1633-37
38. Walker LM, Phogat SK, Chan-Hui P-Y, et al. (2009). Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326(5950): 285-89
39. Liu M, Yang G, Wiehe K, et al. (2015). Polyreactivity and autoreactivity among HIV-1 antibodies. J. Virol. 89(1): 784-98
40. Huang J, Doria-Rose NA, Longo NS, et al. (2013). Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. Protoc. 8(10): 1907-15
41. Shlomchik MJ, Weisel F. (2012). Germinal center selection and the development of memory B and plasma cells. Immunol. Rev. 247(1): 52-63
42. Verkoczy L, Diaz M, Holl TM, et al. (2010). Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. PNAS 107(1): 181-86
43. Verkoczy L, Chen Y, Bouton-Verville H, et al. (2011). Rescue of HIV-1 broad neutralizing antibodyexpressing B cells in 2F5 VH'VL knockin mice reveals multiple tolerance controls. J. Immunol. 187(7): 3785-97
44. Chen Y, Zhang J, Hwang K-K, et al. (2013). Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J. Immunol. 191(3): 1260-75
45. Allen CDC, Cyster JG. (2008). Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin. Immunol. 20(1): 14-25
46. Trama AM, Moody MA, Alam SM, et al. (2014). HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell HostMicrobe 16(2): 215-26
47. Khalil AM, Cambier JC, Shlomchik MJ. (2012). B cell receptor signal transduction in the GC is shortcircuited by high phosphatase activity. Science 336(6085): 1178-81
48. Myszka DG, Sweet RW, Hensley P, et al. (2000). Energetics of the HIV gp120-CD4 binding reaction. PNAS 97(16): 9026-31
49. Gitlin AD, Shulman Z, Nussenzweig MC. (2014). Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 509(7502): 637-40
50. Kwong PD, Doyle ML, Casper DJ, et al. (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420(6916): 678-82
51. Chen L, Kwon YD, Zhou T, et al. (2009). Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326(5956): 1123-27
52. Crotty S. (2011). Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621-63
53. Liao H-X, Lynch R, Zhou T, et al. (2013). Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496(7446): 469-76
54. Tangye SG, Ma CS, Brink R, et al. (2013). The good, the bad and the ugly-TFH cells in human health and disease. Nat. Rev. Immunol. 13(6): 412-26
55. Crotty S. (2014). T follicular helper cell differentiation, function, and roles in disease. Immunity 41(4): 529-42
56. Dugast A-S, Stamatatos L, Tonelli A, et al. (2014). Independent evolution of Fc-And Fab-mediated HIV-1-specific antiviral antibody activity following acute infection. Eur. J. Immunol. 44: 2925-37
57. Sather DN, Carbonetti S, Malherbe DC, et al. (2014). Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J. Virol. 88(22): 12968-81
58. McLellan JS, Pancera M, Carrico C, et al. (2011). Structure of HIV-1 gp120 V1 V2 domain with broadly neutralizing antibody PG9. Nature 480(7377): 336-43
59. Chun T-W, Murray D, Justement JS, et al. (2014). Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir. PNAS 111(36): 13151-56
60. Lynch RM, Wong P, Tran L, et al. (2015). HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89: 4201-13
61. Fera D, Schmidt AG, Haynes BF, et al. (2014). Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. PNAS 111(28): 10275-80
62. Doria-Rose NA, Schramm CA, Gorman J, et al. (2014). Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509(7498): 55-62
63. McGuire AT, Glenn JA, Lippy A, et al. (2014). Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J. Virol. 88(5): 2645-57
64. Scheid JF, Mouquet H, Feldhahn N, et al. (2009). A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343(2): 65-67
65. McGuire AT, Hoot S, Dreyer AM, et al. (2013). Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210(4): 655-63
66. Garces F, Sok D, Kong L, et al. (2014). Structural evolution of glycan recognition by a family of potent HIV antibodies. Cell 159(1): 69-79
67. McGuire AT, Dreyer AM, Carbonetti S, et al. (2014). Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 346(6215): 1380-83
68. Sanders RW, Vesanen M, Schuelke N, et al. (2002). Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 76(17): 8875-89
69. Harris A, Borgnia MJ, Shi D, et al. (2011). Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. PNAS 108(28): 11440-45
70. Beddows S, Schulke N, Kirschner M, et al. (2005). Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J. Virol. 79(14): 8812-27
71. Sanders RW, Derking R, Cupo A, et al. (2013). A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 9(9): e1003618
72. Sharma SK, de Val N, Bale S, et al. (2015). Cleavage-independentHIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design. Cell Rep. 11(4): 539-50
73. Crooks ET, Moore PL, Franti M, et al. (2007). A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and solublemonomeric gp120. Virology 366(2): 245-62
74. Crooks ET, Tong T, Osawa K, et al. (2011). Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J. Virol. 85(12): 5825-39
75. Verkoczy L, Kelsoe G, Haynes BF. (2014). HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development. PLoS Pathog. 10(5): e1004073
76. Pappas L, Foglierini M, Piccoli L, et al. (2014). Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature 516(7531): 418-22
77. Jardine J, Julien J-P, Menis S, et al. (2013). Rational HIV immunogen design to target specific germline B cell receptors. Science 340(6133): 711-16
78. Lindqvist M, van Lunzen J, Soghoian DZ, et al. (2012). Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Invest. 122(9): 3271-80
79. Perreau M, Savoye A-L, De Crignis E, et al. (2013). Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210(1): 143-56
80. Locci M, Havenar-Daughton C, Landais E, et al. (2013). Human circulating PD-1+CXCR3-CXCR5+memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39(4): 758-69
81. Cohen K, Altfeld M, Alter G, et al. (2014). Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection. J. Virol. 88(22): 13310-21
82. Herati RS, Reuter MA, Dolfi DV, et al. (2014). Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J. Immunol. 193(7): 3528-37
83. Zotos D, Coquet JM, Zhang Y, et al. (2010). IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J. Exp. Med. 207(2): 365-78
84. Ma CS, Suryani S, Avery DT, et al. (2009). Early commitment of naïve human CD4+ T cells to the T follicular helper (TFH) cell lineage is induced by IL-12. Immunol. Cell Biol. 87(8): 590-600
85. Schneider P. (2005). The role of APRIL and BAFF in lymphocyte activation. Curr. Opin. Immunol. 17(3): 282-89
86. Goenka R, Matthews AH, Zhang B, et al. (2014). Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J. Exp. Med. 211(1): 45-56
87. Isik G, Chung NPY, van Montfort T, et al. (2013). An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. PLoS ONE 8(6): e67309
88. Gupta S, Clark ES, Termini JM, et al. (2015). DNA vaccine molecular adjuvants SP-D-BAFF and SP-DAPRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. J. Virol. 89(8): 4158-69